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Abstract Screening a phage-display single-chain anti-
body library for binding to the breast cancer cell line PM-1
an antibody, scFv173, recognising activated leukocyte cell
adhesion molecule (ALCAM, CD166) was isolated and
its binding proﬁle was characterized. Positive ALCAM
immunohistochemical staining of frozen human tumour
sections was observed. No ALCAM staining was observed
in the majority of tested normal human tissues (nine of
ten). Flow cytometry analyses revealed binding to 22 of
26 cancer cell lines of various origins and no binding to
normal blood and bone marrow cells. Antibody binding
inhibited invasion of the breast cancer cell line MDA-MB-
231 by 50% in an in vitro Matrigel-coated membrane
invasion assay. Reduced growth of tumours in nude mice
was observed in an in vivo model in which the mice were
injected subcutaneously with colorectal carcinoma HCT
116 cells and treated with scFv173 when compared to
control. In summary, we have characterized a novel fully
human scFv antibody recognising ALCAM on cancer cells
and in tumour tissues that reduces cancer cell invasion and
tumour growth in accordance with the hypothesised role
for ALCAM in cell growth and migration control.
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Introduction
An antibody molecule has great potential in diagnosis and
treatment of diseases. Currently 22 monoclonal antibodies
have been approved for therapeutic use in the United States
[1] and more than 200 are in clinical development [2]. Nine
of these have been approved for use in cancer therapy [2].
Development of protein engineering technology has made
it possible to tailor-make antibody molecules with size,
pharmacokinetics, immunogenicity, speciﬁcity, valence
and effector function for the intended application [3]. Only
a small fraction of the antibodies evaluated in clinical
studies are antibody fragments, and of the 54 fragments
currently studied 19 are single-chain fragment V (scFv)
antibodies [1].
In the present study a human antibody phage library was
screened to identify breast cancer-speciﬁc scFv antibodies.
The breast cancer cell line PM-1 was used as target cell line
for selection of antibodies recognising natural folded epi-
topes on the cell surface. Here we report the characterisation
of one scFv (scFv173) antibody found to bind to the cell
adhesion molecule CD166/ALCAM; a transmembrane
glycoprotein member of the immunoglobulin superfamily.
The extracellular part of ALCAM contains ﬁve immuno-
globulin (Ig) domains followed by a transmembrane region
and a short cytoplasmic tail. ALCAM form heterodimers
with CD6 [4] or ALCAM-ALCAM homodimers [5] and is
broadly expressed in human normal tissue and in a number
of cancer cell lines. Altered ALCAM expression has been
reported in different human tumour types such as melanoma
and breast cancer [6]. The scFv173 antibody does not stain
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four normal breast samples. The scFv 173 antibody inhib-
ited breast cancer cell invasion in Matrigel invasion assay,
and showed no effect on cell growth or cell to matrix-
protein adhesion. In a mouse model, treatment with the
scFv173 antibody reduced tumour growth of the human
colorectal carcinoma cell line HCT 116.
Methods and materials
Cells
The human breast carcinoma cell line PM-1 was estab-
lished in our laboratory (Department of Tumor Biology,
Institute for Cancer Research) in 1992 and originates from
pleural ﬂuid aspirated from a breast cancer patient with
advanced disease treated at the Norwegian Radium
Hospital.
Human carcinoma cell lines BU ¨X[ 7], OHS [8], FEMX
[9], EKVX [10], PC-MM1 (kindly provided by Klaus
Pantel, Germany), OSA (kindly provided by Dr. A Thomas
Look, St Jude’s hospital, Memphis, USA), SF-295 and
U-138MG [11], MA11 [12] and D54MG [13] were cultured
in RPMI-1640 medium (BioWhittaker, Verviers, Belgium)
supplemented with 10% FCS (Gibco BRL, Paisley, UK),
2m ML-glutamine (BioWhittaker, Verviers, Belgium) and
10 mM HEPES (BioWhittaker, Verviers, Belgium). Other
cell lines, BT-474, T-47D, MCF-7, MDA-MB-231, SK-
BR-3, HT-29, HCT 116, HTB-182, H146, SK-MEL-28,
SW900, HeLa, OVCAR-3, SKOV-3, DU145, LNCaP and
LL 86 were obtained from The American Type Culture
Collection (ATCC) and cultivated as described above. Bone
marrow cells were aspirated from the iliac crest of healthy
adult donors with their informed consent and the approval
of the Regional Ethics Committee (REK # S-90128).
Materials
The monoclonal IgG anti-ALCAM antibody MAB656 was
purchased from RnD Systems (Abingdon, UK). Laminin,
ﬁbronectinandBSAwereallfromSigma–Aldrich(StLouis,
MO), gambogic acid (GA) from Biomol International
(PA),N-hydroxysuccinimidyl-6-biotinamidohexanoatefrom
VectorLaboratories(CA),andFITC-conjugatedStreptavidin
fromAmershamBiosciences(GEHealthcare,Oslo,Norway).
Human tumour samples (REK #2.2006.2342) and murine
normal tissue were from Oslo University Hospital Radium-
hospitalet,andnormalhumantissuepurchasedfromBiochain
(CA) or TriStar Technology Group (MD). Buffers, strepta-
vidin–HRPand30,30-diaminobenzidine(DAB)substrateused
for immunochemistry were all from DAKO (Denmark). The
scFv antibodies 173 and 141 were generated in collaboration
with Afﬁtech AS, Oslo, Norway as described below. Other
chemicals were purchased from Merck (Germany).
Cell-based antibody selection (CBAS)
Antibody candidates recognising CD166/ALCAM were
isolated from a human recombinant antibody library [14]
using a cell-based screening method described elsewhere
[15]. The candidates were analysed, and the most promis-
ing clones were improved in soluble scFv format for
increased characteristics, resulting in the generation of
scFv173 and scFv141.
Expression and puriﬁcation of scFv in E. coli
ScFvs clones 141 and 173 were expressed for screening,
analysis and puriﬁcation in the secretion vector pHOG21
[16] and also puriﬁed according the methods described
there.
For micro-scale expression, clones were expressed in 96
deep well format (100 ll volume) overnight at 30C with
0.1 mM IPTG using the pHOG 21 system. The next day the
plates were centrifuged (10 min at 3,2209g,4 C) and the
supernatants containing the expressed scFv were used in
further experiments without further puriﬁcation.
Biotinylation
Biotinylation was performed according to Warren et al
[17]. After diluting the scFv in PBS to 800 lg/ml, ﬁvefold
molar excess of N-hydroxysuccinimidyl-6-biotinamido
hexanoate (1 mg/ml in DMSO) was added, followed by
0.5 M sodium borate (pH 8) to a ﬁnal concentration of
0.1 M. The mixture was incubated for 2 h at 37C. The
reaction was blocked by addition of 1 M Tris (pH 8) to
0.2 M ﬁnal concentration and BSA was added to 0.1%.
Free biotin was removed by dialysis overnight against
50 mmol/L Tris–HCl, 150 mmol/L NaCl, 0.5 g/L NaN3
(pH 7.8). The protein concentration was measured using
the BCA assay (Pierce, Thermo Fisher Scientiﬁc, IL).
FACS staining
5 9 10
5 cells were stained with biotinylated scFv173
(0.4 lg) in ice-cold RPMI/10% FCS for 30 min at 4C with
rotation. After washing 3 times with ice-cold RPMI/10%
FCS, the cells were incubated with FITC-conjugated strep-
tavidin (1:75 in PBS/10% FCS) for 1 h at 4C. Cells were
washed three times as described above and analysed on a
FACS (BD LSR II system, BD Biosciences, Franklin Lakes,
NJ). Data acquisition and analysis was performed using
CELLQuestsoftware(BDBiosciences,FranklinLakes,NJ).
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Immunohistochemical studies were carried out with the
biotinylated scFv173 on human normal and tumour sam-
ples, and on murine tissue sections.
Frozen tissue sections were air dried and stored frozen.
After thawing, the slides were ﬁxed for 10 min in ice-cold
acetone, washed with buffer and blocked for 10 min at
room temperature (RT) with biotin blocking system part
one. After washing thoroughly, the sections were incubated
for 10 min at RT with biotin blocking system part two.
After washing thoroughly, sections were incubated with
biotinylated scFv173 (16 lg/ml in ChemMate antibody
diluent) overnight at 4C. Next day the sections were
washed, incubated with HRP–streptavidin complex for 1 h
at RT and subsequently washed before the sections were
stained with DAB + chromatin substrate, counterstained
with hematoxylin and mounted. Negative control sections
were treated as described above except for the incubation
with primary antibody.
Cell viability assay (MTS assay)
The CellTiter 96 AQueous One Solution Cell Proliferation
Assay (Promega, Madison, WI) was used to determine the
number of viable cells in proliferation assays as described
by the manufacturer. Brieﬂy, the cells were seeded in 96-
well plates in a concentration optimised for each cell line.
Next day the medium was replaced with serum-reduced
growth medium added antibodies in the range from 1 lM
to 1 pM. The cells were incubated as indicated in results,
medium was changed and MTS added to each well. The
plates were incubated for 1–4 h at 37C before the absor-
bance was read at 490 nm in a Wallac Victor2 plate reader
(Perkin Elmer, Waltham, MA).
Adhesion
Cells were incubated with scFv antibodies at 4Co na
rotating device for 30 min. The cells were then seeded
into a 96-well plate pre-coated for 2 h at 37C with either
laminin or ﬁbronectin at 1 lg protein per cm
2. After
seeding, the cells were allowed to adhere for 1 h before
half of the wells are washed twice with PBS. The plates
were incubated either at 4- or at 37C since the scFv173
antibody is rapidly internalized at 37C (Online resource,
Fig. 4). At 4C the internalization of membrane proteins
is highly reduced. The number of cells was quantiﬁed
using the MTS assay and incubated for 1–4 h at 37C
before the plates were read as described over. Adhesion
of antibody-treated cells were represented as the ratio of
bound cells (washed wells) and total number of cells
seeded (not washed), and compared to the ratio obtained
for control cells without antibodies added. The number of
cells seeded and the adhesion time was optimised for each
cell line.
Invasion
BD BioCoat Matrigel invasion chambers (BD Biosciences,
Franklin Lakes, NJ) were used essentially as described by
the manufacturer. The cells were labelled with
3H-thymidine
(1:200 dilution of 1 mCi stock) for 24 h before they were
detached using EDTA. The cells were resuspended in RPMI
medium with 4% FCS and mixed with antibodies before
5 9 10
4 cells were seeded in the upper part of the invasion
chamber. The bottom wells contain RPMI medium with 4%
FCS. After 48 h incubation cotton tip swabs were used to
harvest the cells on each side of the ﬁlter and the samples
counted in a scintillation counter. The ratio of invading
cells over non-invading cells was compared between the
various treatments. The anti-ALCAM antibody (RnD sys-
tems, Abingdon, UK) was used in a concentration of 10 lg
to 1 9 10
5 cells. The amount of antibody is the same as
recommended by the manufacturer for use in an adhesion
blockade assay. The scFv antibodies were used in compa-
rable dose (20 lgt o19 10
5 cells) to compensate for lower
avidity since these antibodies only have one binding site per
molecule.
Animal model
Human HCT 116 colorectal carcinoma cells, 2.5 9 10
6
cells in 200 ll buffer, were injected subcutaneously (s.c.)
into the ﬂank of in-house breed Balb-c nu/nu mice on day
1. Antibody treatment started on day 2 and was repeated on
days 3–5 and days 8–12 (in total 9 antibody injections).
The scFv173 antibody was injected s.c. on one ﬂank and
for control, 200 ll antibody storage buffer (PBS with
50 mM imidazole and 1% BSA) was injected on the other
side. In another experiment, tumour cells were injected on
one side only to exclude inﬂuence of the treatment on the
cells on the other side and the mice were divided in two
groups treated either with buffer or with antibody. The
amount of antibody per injection is described in the fol-
lowing section. Housing and all procedures involving ani-
mals were performed according to protocols approved by
the animal care and use committee, in compliance with the
National Committee for Animal Experiments guidelines on
animal welfare.
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Antigen detection on cells and tissues
ScFv173 was characterized using ﬂow cytometry with
respecttoitsbindingtovariousnormalandtumourcelllines,
and freshly isolated human cells. As shown in Table 1,
scFv173boundtoallthebreasttumourcelllines,aswellasto
the majority of the other cancer cell lines tested. The anti-
body did not bind to normal bone marrow cells, but binding
was observed to the human ﬁbroblast cell line LL86 in
accordance with ALCAM expression on ﬁbroblasts [18].
Staining of frozen tumour tissue was positive in tumours
of different histologies. The table in Fig. 1a summarises
results from immunohistochemical (IHC) staining of dif-
ferent tumour tissues and in Fig. 1b examples of positive
staining of breast (i), prostate (ii) and ovarian (iii) tumours
are shown. IHC staining of human (Online resource,
Table 1) or murine frozen normal tissue sections did not
show any positive staining except for weak staining of nor-
malhumanbreast.Fourdifferentbreastsampleswerestained
and of these three were negative and one was positive. Fifty-
two patient samples from a panel of breast cancer biopsies
[19] were compared for positive scFv173 staining. IHC
staining was scored on a scale from 0 to 3+, where 0 was no
staining and grades 1+ to 3+ represented increasing staining
asdescribedpreviously[19].Sincethenumberofsamplesin
eachgroupwassmall,theresultswerefurthergroupedintoa
negativegroup(21samples)wherethestainingwasrecorded
as 0 or 1+ and a positive group (31 samples) for staining of
2+ or 3+. The histological grades were only known for 36
samples. In the negative IHC group, 11 of 17 samples were
histological grade 3, compared to 4 of 19 samples in the
positive group (Table 2), showing that loss of positive
ALCAM staining correlated with a more severe histological
tumour grade (p = 0.029, Fisher’s exact test).
Cell growth
The potential effect of the scFv173 antibody on different
aspects of cell growth was tested and no signiﬁcant effects
on DNA synthesis (
3H-thymidine labelling), or on cell
viability (MTS assay), or on the ability of single cells to
form colonies in a clonogenic assay were observed. As an
example, results of testing MDA-MB-231 cells are shown
in Fig. 3a. We conclude that, under the experimental
conditions used, the scFv173 antibody did not inﬂuence
cell growth or colony formation.
Adhesion
We investigated whether addition of scFv173 to various
cell lines inﬂuenced the ability of the cells to adhere to the
extracellular matrix proteins laminin or ﬁbronectin since
ALCAM is classiﬁed as an adhesion molecule. A com-
mercially available anti-ALCAM antibody was used as
positive control. The cells were preincubated with the
antibodies at 4C before seeded in laminin or ﬁbronectin
coated wells. Decreased adhesion to laminin by 44 ± 11%
(SD) at 4C, compared to the control without antibodies
added, was observed in the non-small cell lung cancer cell
line HTB-182 (Fig. 2, p = 0.001). Adhesion at 37C was
Table 1 FACS analysis showing the binding of the biotinylated scFv
173 to breast cancer cell lines, normal bone marrow, and cancer cell
lines of different origin
Tumour tissue Cell line scFv 173
a
Breast MCF-7 +
PM1 ++
SK-BR-3 ++
MA11 +++
BT-474 +++
MDA-MB-231 [+++
T-47D [+++
Colon HT-29 ++
HCT 116 +++
Skin FEMX –
SK-MEL-28 +
Lung BU ¨X–
HTB-182 ++
EKVX [+++
SW900 [+++
H146 [+++
Bone OHS –
OSA [+++
Cervix HeLa –
Ovary SKOV-3 +
OVCAR-3 ++
Prostate PC-MMI +
LNCaP ++
DU145 ++
Brain SF-295 ++
D54MG ++
U-138MG +++
Normal tissue Cell line scFv 173
Fibroblast LL 86 [+++
Bone marrow NBM I –
NBM II –
NBM III –
a The notions +, ++, +++ and[+++ represent respectively 1.5–39,
3–59, 5–109 and[109 increase in median binding signal over the
negative control with streptavidin–FITC. For an example see Online
resource, Fig. 2
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cell lung cancer cell line EKVX and two ovarian cancer
cell lines, OVCAR3 and SKOV3, were tested. These cell
lines express different amounts of ALCAM (Table 1) and
no statistically signiﬁcantly altered adhesion to laminin
was observed with any of the three cell lines. We conclude
that, although scFv173 reduced the adhesion of HTB182,
this antibody most likely does not inhibit adhesion of cells
to extracellular matrix proteins. Adhesion of the four cell
linestoﬁbronectinwerenotstatisticallysigniﬁcantlyaffected
by scFv173 (Online resource, Fig. 4).
Invasion
Invasion studies were performed in BD BioCoat Matrigel
invasion chambers using the highly invasive breast cancer
cell line MDA-MB-231. Prior to this we found that neither
cell viability nor adhesion to laminin of these cells were
affected by scFv173 (Fig. 3a, b). However, scFv173 in-
hibited invasion of MDA-MB-231 cells by approximately
50%, in three independent experiments, compared to that
observed in the controls without antibody (Fig. 3c). The
monoclonal anti-ALCAM antibody did reduce the invasion
to the same extent as scFv173. Another single-chain Fv
antibody scFv141, targeting the transferrin receptor and
isolated in the same screening as scFv173, did not signiﬁ-
cantly alter the invasion when compared to the buffer
control.
To investigate whether scFv173 inhibited invasion of
the other cell lines used in the adhesion assay their ability
to migrate was tested. After 48 h around 45% of the seeded
OVCAR-3 cells migrated to the bottom of the ﬁlter, 10%
of HCT 116 cells and only 3% of the HTB-182 cells. In
the Matrigel assay there was a tendency that scFv173
decreased also the invasion of OVCAR cells, although
statistical signiﬁcance was not obtained (Online resource,
Fig. 5). No invasion through Matrigel was observed with
HCT 116 colorectal carcinoma cells.
7 7 Prostate (ii)
1 0 Sarcom
11 0 Malignant 
melanom
16 1 Brain
4 2 Lung
5 3 Colon
14 11 Ovarian (iii)
52 46 Breast (i)
Tested Positive
i
ii
iii
A
B
Fig. 1 Immunohistochemical ALCAM staining of frozen human
tumour tissue biopsies. Positive staining (a) was observed in 46 of 52
representative breast tumour samples, in all prostate tumour samples,
and in 11 of 13 ovarian tumour samples. In b examples of positive
staining of breast (i), prostate (ii) and ovarian (iii) tumour tissue are
shown. IHC staining was scored on a scale from 0 to 3+ where 0 was
no staining and grades 1+ to 3+ represented increasing staining
Table 2 Cross-tabulation of scFv173 IHC staining and histological
grading of breast tumour samples
IHC staining Histological grade
a Total
12 3
scFv173 negative 1 5 11 17
scFv173 positive 4 11 4 19
Total 5 16 15 36
a Other prognostic factors investigated were age, side, lymph node
metastasis, distant metastasis, death, and tumour diameter. None of
these factors associated with scFv173 staining
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Effects of the fully human scFv173 single-chain antibody
on tumour formation were tested in a Balb-c nu/nu model
where the antibody was injected subcutaneously in vicinity
to the forming tumour. We chose to use the colorectal
carcinoma cell line HCT 116 since the tumour take rate and
growth are fast [20]. HCT 116 cells express ALCAM
(Table 1) and three of ﬁve tested colon tumour tissues
displayed strong positive ALCAM staining in IHC (Fig. 1).
A pilot experiment was performed where three mice were
injected with cells on both ﬂanks and next day 200 lg
antibody or buffer was injected, and the treatment was
repeated every day for 8 days during the ﬁrst 2 weeks.
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Fig. 2 Effects of scFv173 on adhesion of cells to extracellular matrix
proteins. Adhesion assay of cells (HTB-182, EKVX, OVCAR-3 or
SKOV-3) preincubated with antibodies and seeded in 96-well tissue
culture plates coated with laminin. The cells were allowed to adhere
for 1 h before half of the wells were washed twice with PBS and the
number of cells in each well quantiﬁed using MTS. Inhibition of cell
adhesion to laminin is represented as the ratio of MTS measurement
in wells washed with PBS and wells that were not washed. Black bars
shows adhesion at 4C and white bars adhesion at 37C. For
comparison the ratio of control wells without antibodies (scFv173 or
anti-ALCAM from RnD systems) added is 100%. Five independent
experiments, each with triplicate wells
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Fig. 3 Effects of scFv173 on MDA-MB-231 cell viability, adhesion
and Matrigel invasion assay. a Breast cancer MDA-MB-231 cells
were added antibody, scFv173 or scFv141, to a ﬁnal concentration of
1 lM( black bar) or 1 nM (white bar) and the cell viability measured
after 48 h in a MTS assay. Control cells were grown with ordinary
medium or added gambogic acid (GA) known to induce apoptosis in
tumour cell lines. b Cell adhesion to laminin at 4C as previously
described using MDA-MB-231 cells. c
3H-thymidine labelled MDA-
MB-231 cells were mixed with antibodies prior to seeding and
harvested after 48 h. The ratio of invading cells over non-invading
cells in treated wells are normalised to the ratio in untreated wells.
The bars represents the average with standard deviation of 2 (a, b)o r
3( c) independent experiments with triplicate wells for each treatment.
p values were determined using a two tailed t test comparing controls
and scFv173-treated cells or controls and anti-ALCAM treated cells
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treated with antibody, but the ﬂanks treated with buffer only
showed tumour take and measurable growth already on
day 4 (Fig. 4a). When the mice were killed on day 35 there
were still no tumours on the antibody-treated ﬂanks. The
experiment was repeated with eight animals treated with
1/10 of the initial antibody dose (20 lg antibody per injec-
tion) or buffer control. Even with this low antibody dose
reduced growth of the tumours treated with antibody was
observed (Fig. 4b). In an independent experiment, experi-
mental groups of six mice were injected with cells on one
ﬂank only and treated with buffer or antibody to exclude
inﬂuence of the treatment on the cells on the opposite ﬂank.
On day 34 after cell injection four mice in the control
group were killed, since the tumour had reached the
maximum tolerated size, compared to one animal treated
with scFv173. Reduced tumour volume was observed
(Fig. 4c) and, as indicated on the ﬁgure, the tumours in the
antibody-treated group increased from 100 to 400 mm
3 in
approximately 16 days compared to 8 days in the control
group, suggesting that the scFv173 inhibited both tumour
onset and growth in the HCT 116 colorectal cancer model.
Discussion
Our overall goal in this project was to identify antibodies
for possible use in diagnostics and therapy utilizing phage-
display technology and cell-speciﬁc antibody selection.
Two high-afﬁnity antibodies scFv173 and scFv141 were
initiallycharacterized;respectivelyrecognisingtheALCAM
molecule and the transferrin receptor. The ALCAM anti-
body was most promising and initial characterisation using
ﬂow cytometry revealed binding to most of the cancer cell
lines tested, and in addition to LL 86, ﬁbroblasts isolated
from normal tissue from an osteosarcoma patient. Evalu-
ation using IHC revealed cancer-speciﬁc binding and a
correlation between ALCAM positivity and histological
tumour grade. The scFv173 antibody showed two unique
features; it inhibited breast cancer cell invasion through
Matrigel and reduced tumour growth in a mouse model.
To identify novel antibodies other groups have used
similar approaches to ours and isolated antibodies targeting
both antigens. For example did 84 antibodies react with 21
distinct antigens expressed on various carcinomas, among
these antibodies 11 recognised ALCAM and 6 the trans-
ferrin receptor [21] showing that these proteins are highly
antigenic and over-expressed in carcinomas. ALCAM scFv
antibodies have also been produced after panning of ovarian
[22] and prostate [23] cancer cells. These antibodies were
selected for internalization and have been used as immu-
notoxin [22] or for delivery of liposomal drugs [24]. Our
antibody fulﬁls two important prerequisites for use as
targeting molecule to cancer cells; it is internalized (Online
resource, Fig. 6), and, importantly, it does not stain normal
human tissues except for weak staining of one of four
normal breast samples. Another anti-ALCAM scFv was
also found negative for normal tissue staining except for
bronchial epithelial staining [25]. The antibody libraries
were in both cases pre-screened for binding to normal cells
to exclude those antibodies reacting with common anti-
genes. It seems that most antigens are expressed in a low
basal level by normal cells and that transformation into
tumour cells results in overexpression of these antigens. In
this context, scFv antibodies have an advantage compared
to monoclonal antibodies in that they have one antigen
binding site and thus lower avidity which may result in less
binding to normal cells with low expression of the target. To
increase tumour speciﬁcity it is possible to engineer anti-
body fragments recognising more than one antigen. Other
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Fig. 4 Inhibitory effect of scFv173 on in vivo tumour growth. The
colon cell line HCT 116 and the scFv173 antibody were injected s.c.
in Balb-c nu/nu mice. a–c shows the increase in average tumour
volume with standard deviation of buffer treated (black box)o r
scFv173 treated (white box) tumours followed from injection of cells
until the mice were killed. The scFv173 antibody was dissolved in
PBS pH 7.4 added 50 mM imidazole and 1% BSA and this buffer was
used as control. The bars represent the standard deviation
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conventional antibodies are that the smaller size allows
deeper and more rapid penetration into the tumour, and
binding to epitopes not accessible to full size antibodies.
Due to the small size of the scFv antibodies they are rapidly
cleared from the circulation. Under some circumstances this
is an advantage, for example to reduce toxicity when the
scFv is used as immunotoxin, but this may also be a dis-
advantage since too few molecules may reach the target site
to obtain a therapeutic relevant dose [1].
The scFv173 antibody inhibited Matrigel invasion of
MDA-MB-231 cells and in vivo HCT 116 tumour growth.
This is in agreement with effects observed when soluble
ALCAM [26] or truncated ALCAM [27] were over-
expressed in metastatic melanoma cells. Expression of
soluble ALCAM made the cells less invasive. This soluble
version consist of the N-terminal Ig-domain that together
with the neighbour domain is responsible for ligand bind-
ing [18] and important for ALCAM mediated cell–cell
adhesion[5].Reducedprimarytumourgrowth,butincreased
metastasis to the lung was observed when melanoma
cells transfected with N-terminally truncated ALCAM
were injected s.c. in a nude mouse model. In this truncated
ALCAM molecule two domains most distal to the mem-
brane were deleted. Over expression of the two ALCAM
variants inhibited the MMP2 activation cascade via inhi-
bition of MMP2 activity caused by reduced MMP14
expression [26]. In contrast, incubation of MDA-MB-231
cells or HCT 116 cells with the scFv173 did not result
in reduced MMP2 activation or increased TIMP-2 levels
as assayed by zymography and reverse zymography,
respectively (Online resource, Fig. 7) suggesting that the
observed reduced Matrigel invasion and tumour growth
was not due to inhibition of MMP2 activity.
Cell adhesion molecules are involved in cell–cell
interactions and cell–extracellular matrix interactions. It
has been hypothesised that ALCAM forms a network in the
plasma membrane [28] and that the ALCAM variants
disturb this network that seems to be important for cell–cell
interacting for primary tumour growth. We hypothesise
that the scFv173 antibody in a similar manner disturbs the
ALCAM–ALCAM network and thereby reduce in vivo
primary tumour growth.
Altered ALCAM expression has been suggested as
prognostic indicator in breast carcinoma but some discrep-
ancy exists as to whether low ALCAM mRNA expression
[29] or high ALCAM protein expression [30] is a bad
prognostic indicator. In a recently published paper both
mRNA and protein expression was measured and a positive
correlationobtained [31] clarifying thatdiscordantALCAM
mRNAandproteinexpressioncannotexplaintheconﬂicting
reported results. Several studies point at increased ALCAM
expressioninthecytoplasmasanegativeprognosticfactorin
other cancers for example in oral [32], bladder [33], ovarian
[34] and pancreatic cancer [35]. In other tumour types high
ALCAM protein expression is associated with poor prog-
nosis [6]. In a study of colorectal cancer patients examining
ALCAM expression by immunohistochemistry (IHC) short-
ened survival time was observed in patients with membra-
nous and cytoplasmic ALCAM staining when compared to
patients without membranous ALCAM staining [36]. We
observed reduced positive ALCAM staining in frozen
sections of human breast cancer of high histological grade
comparedtothoseoflowergrade.Noconcomitantincreased
intracellularstainingwasobserved.Thisisinagreementwith
published results [29, 37] but not with data showing that
increased cytoplasmic ALCAM expression is linked to
higher tumour grading [30]. Since we used live cells to
screenforantigen–antibodybindingonecouldspeculatethat
theepitoperecognisedbyscFv173isunavailableforbinding
thecytoplasmicformofALCAM.Themajorityofreportson
cytoplasmic ALCAM staining have been done on formal-
dehyde ﬁxedparafﬁnembedded sections.Ourantibody does
not recognise its epitope under such conditions indicating
that the epitope is susceptible to chemical alteration induced
by formaldehyde. We suggest that the conﬂicting results are
causedbytheuseoffrozentissuesversusformaldehydeﬁxed
parafﬁn embedded cancer tissues and not due to the use of
different antibodies. This is supported by data reporting that
one monoclonal antibody gave opposite results on frozen
tissue [29] compared to formaldehyde ﬁxed tissue [30].
In conclusion, the potential of the new fully human scFv
anti-ALCAM antibody as a therapeutic candidate is sup-
ported by its in vivo anti-tumour activity in colorectal car-
cinoma and its negative staining of normal human tissue.
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